Sygnis Pharma

Activities: Research & Development

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Analysis

SYGNIS AG announces the launch of TrueHelix

The first tool on the TrueHelix platform addresses sample contamination, a key pitfall in NGS workflows
Ingredients

SYGNIS AG reinforces its proteomics portfolio with two patents granted in Europe and China

Granted patents confirm innovation and novelty of proteomics product range
Research & Development

Sygnis strengthens management team with appointment of Heikki Lanckriet

He joins the DNA amplification and sequencing firm as joint CEO and Chief Scientific Officer
Subscribe now